



October 1, 2020

Company name: SanBio Co., Ltd.

Representative: Keita Mori, Representative Director
and President

(TSE Mothers Code: 4592)

Contact: Yoshihiro Kakutani, Corporate Officer
of Management Administration
(TEL. +81-3-6264-3481)

Notice regarding Establishment of a Singaporean Subsidiary

SanBio Co., Ltd. (hereafter, “the Company”) hereby announces that at a Board of Directors meeting held on October 1, 2020, it has resolved to establish a subsidiary in Singapore as detailed below.

1. Reason for establishment of subsidiary

The Company has decided to establish the subsidiary to build an operating structure based in Singapore to facilitate the establishment of a global supply chain for the Group’s products, including regenerative cell medicine SB623, as well as the expansion of sales regions and business development activities in Asia.

2. Overview of subsidiary to be established

(1) Company name	SanBio Asia Pte. Ltd.
(2) Address	TBA
(3) Representative	Hiroshi Yamamoto Corporate Officer, Head of Japan/Asia Business, SanBio Co., Ltd.
(4) Business	Global supply of pharmaceuticals, pharmaceutical sales and business development in Asia
(5) Capital	SGD400,000 (about JPY32,000,000)
(6) Date to be established	February 1, 2021 (tentative)
(7) Stake	100% owned by the Company

3. Outlook

The establishment of subsidiary will have only a marginal impact on the Group’s earnings performance for the fiscal year ending January 2021.